Yasser Osman, Tarek Elsharkawy, Tariq Mohammad Hashim, Jumana Abdulwahab Alratroot, Fatima Aljindan, Liqa Almulla, Hind Saleh Alsuwat, Waad Mohammed Al Otaibi, Fatma Mohammed Hegazi, Abdallah M Ibrahim, J Francis Borgio, Sayed AbdulAzeez
{"title":"Study of Single Nucleotide Polymorphisms Associated with Breast Cancer Patients among Arab Ancestries.","authors":"Yasser Osman, Tarek Elsharkawy, Tariq Mohammad Hashim, Jumana Abdulwahab Alratroot, Fatima Aljindan, Liqa Almulla, Hind Saleh Alsuwat, Waad Mohammed Al Otaibi, Fatma Mohammed Hegazi, Abdallah M Ibrahim, J Francis Borgio, Sayed AbdulAzeez","doi":"10.1155/2022/2442109","DOIUrl":null,"url":null,"abstract":"<p><p>The aim of this study is to investigate the single nucleotide polymorphisms (SNPs) associated with breast cancer in our population of Arab patients. We investigated 26 breast cancer patients and an equal number of healthy age- and sex-matched control volunteers. We examined the exome wide microarray-based biomarkers and screened 243,345 SNPs for their possible significant association with our breast cancer patients. Successfully, we identified the most significant (<i>p</i> value ≤9.14 × 10<sup>-09</sup>) four associated SNPs [<i>SNRK</i> and <i>SNRK-AS1-</i>rs202018563G; <i>BRCA2-</i>rs2227943C; <i>ZNF484-</i>rs199826847C; and <i>DCPS-</i>rs1695739G] among persons with breast cancer versus the healthy controls even after Bonferroni corrections (<i>p</i> value <2.05 × 10<sup>-07</sup>). Although our patients' numbers were limited, the identified SNPs might shed some light on certain breast cancer-associated functional multigenic variations in Arab patients. We assert on the importance of more extensive large-scale analysis to confirm the candidate biomarkers and possible target genes of breast cancer among Arab ancestries.</p>","PeriodicalId":46159,"journal":{"name":"International Journal of Breast Cancer","volume":null,"pages":null},"PeriodicalIF":1.6000,"publicationDate":"2022-10-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9578870/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Breast Cancer","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1155/2022/2442109","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/1/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
The aim of this study is to investigate the single nucleotide polymorphisms (SNPs) associated with breast cancer in our population of Arab patients. We investigated 26 breast cancer patients and an equal number of healthy age- and sex-matched control volunteers. We examined the exome wide microarray-based biomarkers and screened 243,345 SNPs for their possible significant association with our breast cancer patients. Successfully, we identified the most significant (p value ≤9.14 × 10-09) four associated SNPs [SNRK and SNRK-AS1-rs202018563G; BRCA2-rs2227943C; ZNF484-rs199826847C; and DCPS-rs1695739G] among persons with breast cancer versus the healthy controls even after Bonferroni corrections (p value <2.05 × 10-07). Although our patients' numbers were limited, the identified SNPs might shed some light on certain breast cancer-associated functional multigenic variations in Arab patients. We assert on the importance of more extensive large-scale analysis to confirm the candidate biomarkers and possible target genes of breast cancer among Arab ancestries.
期刊介绍:
International Journal of Breast Cancer is a peer-reviewed, Open Access journal that provides a forum for scientists, clinicians, and health care professionals working in breast cancer research and management. The journal publishes original research articles, review articles, and clinical studies related to molecular pathology, genomics, genetic predisposition, screening and diagnosis, disease markers, drug sensitivity and resistance, as well as novel therapies, with a specific focus on molecular targeted agents and immune therapies.